Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution...
Những tác giả chính: | Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, MR, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S, Harris, A, Bottini, A, Berruti, A, Generali, D |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
2013
|
Những quyển sách tương tự
-
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Bằng: Allevi, G, et al.
Được phát hành: (2013) -
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Bằng: Generali, D, et al.
Được phát hành: (2009) -
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Bằng: Generali, D, et al.
Được phát hành: (2008) -
Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
Bằng: Generali, D, et al.
Được phát hành: (2011) -
Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
Bằng: Fox, S, et al.
Được phát hành: (2006)